ArrowMark Colorado Holdings’s Regeneron Pharmaceuticals REGN Stock Holding History

ArrowMark Colorado Holdings’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-3,048	Closed	-$861K	–	315
2014 Q2	$861K	Hold	3,048	–	–	0.02%	212
2014 Q1	$915K	Sell	3,048 -1,242	-29%	-$383K	0.03%	199
2013 Q4	$1.18M	Buy	4,290 +300	+8%	+$86.3K	0.04%	194
2013 Q3	$1.25M	Buy	3,990 +370	+10%	+$97.3K	0.04%	196
2013 Q2	$814K	Buy	+3,620	New	+$843K	0.22%	69

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

ArrowMark Colorado Holdings's REGN Position: Q3 2014 in Review

ArrowMark Colorado Holdings sold out of Regeneron Pharmaceuticals (REGN) in Q3 2014, closing a stake of 3,048 shares — an estimated $861K sold.

ArrowMark Colorado Holdings first reported a position in REGN in Q2 2013 and held it in 5 quarters. The position peaked at $1.25M in Q3 2013. 474 funds tracked by Wall St. Rank hold REGN as of Q3 2014.

ArrowMark Colorado Holdings reported no remaining Regeneron Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
ArrowMark Colorado Holdings sold 3,048 Regeneron Pharmaceuticals shares in Q3 2014, an estimated $861K.
ArrowMark Colorado Holdings first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 5 quarters.
ArrowMark Colorado Holdings's Regeneron Pharmaceuticals position peaked at $1.25M in Q3 2013.
474 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2014.

Based on ArrowMark Colorado Holdings's 13F filing for Q3 2014, filed 14 Nov 2014.